AskMuncher
2 years ago
$MYNDF MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
Press Release | 12/15/2021
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
PR Newswire
VANCOUVER, BC, Dec. 15, 2021
VANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: "A Method of Immune Modulation by Modulating a Specific Gene."
Mynd Life Sciences logo (CNW Group/Mynd Life Sciences Inc.)
"MYND's is profoundly different than the majority of the Psychedelics' sector. We are seeking intellectual property protection through the pursuit of patents by validation of our Intellectual Property through research and development," stated Dr. Lyle Oberg, MD, CEO of MYND. "As this sector grows and matures and as MYND develops our novel drug development pipeline, the creation of a solid intellectual property portfolio is the key to creating lasting shareholder value. MYND's ability to obtain patent protection will allow us to move towards the filing of Innovative New Drug (IND) application and approval status."
According to the World Health Organization, over 300,000,000 people globally suffer from depression and other psychiatric disorders. Major Depressive Disorder and Treatment Resistant Depression have a greater than 50% chance of relapse using conventional methods of treatment. Traditional treatments focus solely on symptom suppression, not the root cause. Covid-19 has accelerated the ongoing mental health crisis around the world. In a June 2020 CDC survey, 31% of US respondents reported symptoms of anxiety or depression, 13% started/increased substance use, 26% reported stress-related symptoms, 11% reported serious thoughts of suicide in preceding 30 days. These numbers are double pre-pandemic levels.
The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent offices in what is called the "national phase". https://www.uspto.gov/patents/basics/international-protection/patent-cooperation-treaty
MYND MARKETING AND INVESTOR RELATIONS AGREEMENTS
MYND has retained Hybrid Financial Ltd. ("Hybrid") to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for MYND and to broaden it's reach within the biotech drug research and development investment community. Hybrid has been engaged for a monthly fee of $22,500 by the Company for an initial period of twelve months, commencing November 16, 2021.
ABOUT MYND LIFE SCIENCES INC.
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact/.
CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com
Forward-Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mynd-life-sciences-provides-update-on-depression-gene-modulation-pathway-patent-application-301445299.html
AskMuncher
2 years ago
$MYNDF MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
Press Release | 12/15/2021
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
PR Newswire
VANCOUVER, BC, Dec. 15, 2021
VANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: "A Method of Immune Modulation by Modulating a Specific Gene."
Mynd Life Sciences logo (CNW Group/Mynd Life Sciences Inc.)
"MYND's is profoundly different than the majority of the Psychedelics' sector. We are seeking intellectual property protection through the pursuit of patents by validation of our Intellectual Property through research and development," stated Dr. Lyle Oberg, MD, CEO of MYND. "As this sector grows and matures and as MYND develops our novel drug development pipeline, the creation of a solid intellectual property portfolio is the key to creating lasting shareholder value. MYND's ability to obtain patent protection will allow us to move towards the filing of Innovative New Drug (IND) application and approval status."
According to the World Health Organization, over 300,000,000 people globally suffer from depression and other psychiatric disorders. Major Depressive Disorder and Treatment Resistant Depression have a greater than 50% chance of relapse using conventional methods of treatment. Traditional treatments focus solely on symptom suppression, not the root cause. Covid-19 has accelerated the ongoing mental health crisis around the world. In a June 2020 CDC survey, 31% of US respondents reported symptoms of anxiety or depression, 13% started/increased substance use, 26% reported stress-related symptoms, 11% reported serious thoughts of suicide in preceding 30 days. These numbers are double pre-pandemic levels.
The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent offices in what is called the "national phase". https://www.uspto.gov/patents/basics/international-protection/patent-cooperation-treaty
MYND MARKETING AND INVESTOR RELATIONS AGREEMENTS
MYND has retained Hybrid Financial Ltd. ("Hybrid") to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for MYND and to broaden it's reach within the biotech drug research and development investment community. Hybrid has been engaged for a monthly fee of $22,500 by the Company for an initial period of twelve months, commencing November 16, 2021.
ABOUT MYND LIFE SCIENCES INC.
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact/.
CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com
Forward-Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mynd-life-sciences-provides-update-on-depression-gene-modulation-pathway-patent-application-301445299.html
TFMG
5 years ago
MYND ANALYTICS STOCK PRICE COULD DOUBLE
INVESTORS ARE REWARDED FOR LOYALTY WITH MAJOR STOCK MOVES ON MERGER CLARITY
Yutaka Niihara, MD , MPH, CEO and Chairman of Emmaus, stated, "We are very grateful for this opportunity to merge with MYnd Analytics . The anticipated listing on Nasdaq via the merger with MYnd Analytics is an important step to maximize value for shareholders. We look forward to sharing with the public markets our progress on the market acceptance of Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older. Endari addresses a $3 billion global market. In addition to the treatment of sickle cell disease, we believe our platform technology has the potential to address other major clinical indications such as diverticulosis."
Robin Smith, Chairman of MYnd Analytics , commented, "We are pleased with the progress of the merger and spin-off transaction, which remains on track to close before the end of this month, subject to approval of shareholders. We believe this transaction will drive significant value for all shareholders, and we will provide further updates following the respective shareholder meetings."
AVERAGE ANALYSTS PRICE TARGET $4
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
MYnd Analytics , Inc. operates as a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. It provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioural disorders, includes depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders. The company was founded by Leonard J. Brandt and Brain McDonald on March 20, 1987 and is headquartered in Aliso Viejo, CA.
namah sivaya
5 years ago
MYnd Analytics and Emmaus Life Sciences Report Progress on Merger and Spin-off Transaction
Merger and Spin-off Transaction on Track to Close by End of July
New Spin-Off Record Date Set for July 15, 2019
MISSION VIEJO, Calif. and TORRANCE, Calif., July 09, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (Nasdaq: MYND) , a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease treatment, today provided an update on the planned merger and spin-off transaction announced on January 7, 2019. The respective special stockholder meetings will be held today, July 9, 2019, to consider approval of the proposed merger and spin-off transaction. Subject to approval by holders of record of the companies at the respective special stockholder meetings, MYnd will issue a number of shares of common stock to the current Emmaus shareholders, which will result in MYnd shareholders retaining 5.9% of the fully diluted shares of the 'New Emmaus' post-closing and a pro rata distribution of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019. The companies have set a new Spin-Off Record Date of July 15, 2019 in order to comply with certain NASDAQ and DTC requirements. Those individuals who hold shares at the close of trading on the 16th of July will receive the Telemynd dividend. MYnd shares will trade ex-dividend on July 17, which means that persons who purchase MYnd shares on July 17 will not receive shares of Telemynd.
It is expected that on July 16 and July 17, the necessary steps will occur to spin off Telemynd with the current MYnd assets, effectuate the merger and any adjustments needed to meet NASDAQ listing standards and commence trading on July 18, 2019 under the new symbol “EMMA.”
Yutaka Niihara, MD, MPH, CEO and Chairman of Emmaus, stated, “We are very grateful for this opportunity to merge with MYnd Analytics. The anticipated listing on Nasdaq via the merger with MYnd Analytics is an important step to maximize value for shareholders. We look forward to sharing with the public markets our progress on the market acceptance of Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older. Endari addresses a $3 billion global market. In addition to the treatment of sickle cell disease, we believe our platform technology has the potential to address other major clinical indications such as diverticulosis.”
Robin Smith, Chairman of MYnd Analytics, commented, “We are pleased with the progress of the merger and spin-off transaction, which remains on track to close before the end of this month, subject to approval of shareholders. We believe this transaction will drive significant value for all shareholders, and we will provide further updates following the respective shareholder meetings.”
http://www.globenewswire.com/news-release/2019/07/09/1880221/0/en/MYnd-Analytics-and-Emmaus-Life-Sciences-Report-Progress-on-Merger-and-Spin-off-Transaction.html
namah sivaya
5 years ago
MYND warrants MYNDW amended strike price from $5.25 to $2.00!
On June 28, 2019, the Company amended the terms of its existing Warrant Agreements, dated as of July 19, 2017 and July 25, 2017, which were entered into between the Company and American Stock Transfer & Trust Company, as warrant agent (the “Warrant Agreements”), to reduce the exercise price of the warrants issued pursuant to the Warrant Agreements from $5.25 to $2.00 per share, effective upon the consummation of the Merger, for a period of one year.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=12988570&ds=2
namah sivaya
5 years ago
Robert Plotkin, Chief Executive Officer and Founder of Arcadian, will present a company overview at 2019 Telemed Leadership Forum, entitled, “Transforming Healthcare Delivery,” on Thursday, April 4th at 3:30pm ET followed by a panel discussion entitled, “Models of Tele-Behavioral Health Services,” on Thursday April 4th at 4:15pm ET. Mr. Plotkin plans to discuss how technology is being used to improve behavioral healthcare and reduce overall costs to the healthcare system.
MYND could be in the news later this week...
https://finance.yahoo.com/news/ceo-arcadian-telepsychiatry-services-invited-131500913.html
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Don
5 years ago
ThoughtPower
5 years ago
TheFinalCD
5 years ago
Hot Features
Premium
